Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD

Video

Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease.

Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease (KSHV-MCD).

KSHV is able to infect endothelial cells, B-cells, and concurrent tumors, Uldrick says. Results from a study showed that 95% of patients treated with rituximab plus liposomal doxorubicin will have a complete resolution of symptoms, while nearly 90% will have normalization of all laboratory abnormalities that are caused by MCD.

Twenty-two patients were treated with rituximab plus liposomal doxorubicin. Long-term follow-up of this data demonstrates that patients present with a wide range of symptoms, such as fevers, anemia, edema, and swelling. Researchers sought to determine which baseline factors predicted good long-term outcomes in patients, especially those with HIV-associated and KSHV factors. The only factor that predicted survival was advanced KS, Uldrick adds.

The 5-year overall survivals was 91% for patients without advanced KS and 56% for patients with advanced KS. Additionally, 70% of patients were disease-free after a median of 3 cycles of treatment.

<<<

View more from the 13th International Conference on Malignant Lymphoma

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center